Implants derived from stem cells are potential game-changer in treating type 1 Diabetes
Earlier this month, San Diego-based ViaCyte announced that was conducting human tests using an islet-cell replacement candidate product for patients with type 1 diabetes. The product, PEC-Direct, produces pancreatic progenitor cells that can replace damaged or missing pancreatic cells. |